Canaccord analyst Sumant Kulkami reiterated a Buy rating and $36.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).The analyst commented: "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments